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Abstract
Introduction Male breast cancer accounts for around 1% of all
breast cancer cases but the incidence has risen in recent years.
This study aimed to classify the molecular subtypes of male
breast cancers based on the expression profile of
immunomarkers and to evaluate their association with
clinicopathological features and expression patterns of
epidermal growth factor receptor (EGFR) and nuclear factor κB
(NF-κB).
Methods A total of 42 cases of male breast carcinoma were
examined retrospectively using immunostains for estrogen
receptor (ER), progesterone receptor (PR), cytokeratin 5/6
(CK5/6), EGFR, and NF-κB. Human epidermal growth factor
receptor 2 (HER2) expression was evaluated by immunostaining
and confirmed by fluorescent in situ hybridization (FISH).
Results The luminal A subtype was the most common subtype
in male breast cancer (83%, 35/42), which was followed by the
luminal B subtype (17%, 7/42). Basal-like and HER2+/ER-
subtypes were not identified in this group. All carcinomas
expressed ER and 67% of them were PR+. High nuclear grades
were more common in the luminal B subtype (71%, 5/7) than in
the luminal A subtype (34%, 12/35). The luminal B subtype
carcinomas expressed EGFR (42%, 3/7) and NF-κB (57%, 4/
7) more frequently than the luminal A subtype did (17%, 6/35
and 37%, 13/35, respectively).
Conclusions In our study group, luminal A and B subtypes were
the major subtypes of male breast carcinoma. The
immunophenotypical features of male breast cancer differ from
those of its female counterpart. Luminal B subtype tended to
have high nuclear grade and more frequent expression of EGFR
and NF-κB.
Introduction
Male breast cancer is an uncommon disease, accounting for
approximately 1% of all breast cancer cases and less than 1%
of all malignancies in men [1,2]. The American Cancer Society
estimates that 1,910 men will be diagnosed with breast can-
cer in the USA in 2009 and about 440 men will die from the
disease [3]. Although breast carcinoma in both genders
shares certain characteristics, there are notable differences in
incidence, age distribution, prognosis and survival. The unfa-
vorable overall prognosis in male breast cancer has been
attributed to the older age and advanced tumor stage at the
time of diagnosis [4].
Based on the recent DNA microarray studies on female breast
cancer cases, distinct molecular subtypes of breast carcinoma
were identified with different clinical outcomes [5]. Using an
intrinsic set of 534 genes, Sorlie and colleagues [6] analyzed
the expression profiles of 115 independent breast cancer
specimens and categorized them into the following subtypes:
luminal; human epidermal growth factor receptor 2 (HER2)
over-expressing; normal breast-like; and basal-like. The tumor
subtypes correlated well with clinical outcomes as measured
by overall survival and distal metastasis, with the worst out-
come observed in HER2 over-expressing and basal-like sub-
types [5-7].
CEP: centromeric region of chromosome 17; CK: cytokeratin; DAPI: 4,6-diamidino-2-phenylindole dihydrochloride; EGFR: epidermal growth factor 
receptor; ER: estrogen receptor; FISH: fluorescent in situ hybridization; HER2: human epidermal growth factor receptor 2; IHC: immunohistochem-
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The molecular subtypes of female breast cancer were origi-
nally identified by gene expression analysis using DNA micro-
arrays. However, large-scale subtyping using gene expression
profiling from formalin-fixed, paraffin-embedded samples is not
currently feasible. Therefore, immunohistochemical (IHC)
markers have been used as surrogates for DNA microarray in
subtyping breast cancer. By using a panel of four antibodies
including estrogen receptor (ER), HER1, HER2 and cytokera-
tin 5/6 (CK5/6), Nielsen and colleagues [8] characterized
three IHC-defined subtypes: luminal (ER+, HER2-), HER2
(HER2+), and basal-like (ER-, HER2-, CK5/6+ or HER1+).
Based on more recent gene expression studies, Carey and
colleagues [9] updated IHC subtype definition as luminal A
(ER+ and/or progesterone receptor (PR)+, HER2-), luminal B
(ER+ and/or PR+, HER2+), HER2+/ER- (ER-, PR-, HER2+),
basal-like (ER-, PR-, HER2-, CK5/6+), and unclassified (nega-
tive for all five markers).
In addition to these subtypes, the prognosis of breast cancer
may be affected by expressions of two additional molecular
markers. Epidermal growth factor receptor (EGFR) was
reported to be over-expressed in aggressive female breast
cancer [10-13] and is currently being evaluated in clinical trials
as a potential therapeutic target [14-16]. It was also reported
that transcription factor nuclear factor κB (NF-κB) was acti-
vated in breast cancer cells with over-expressed EGFR [17].
The elevation of NF-κB was speculated to be associated with
unfavorable prognosis by promoting metastasis [18,19], inhib-
iting apoptosis [20], and increasingly resistance to chemother-
apy [21]. Increasing evidence has suggested that NF-κB is a
potential target for the treatment of breast cancer and the pre-
vention of metastasis [22,23].
Despite these advances in female breast carcinoma, our
understanding and treatment strategies for male breast cancer
are limited and generally extrapolated from our knowledge of
female breast cancer. In particular, the molecular subtypes of
male breast cancer have not been studied although the sub-
types were reportedly associated with both biological and clin-
ical behaviors in female breast cancer. This article reports our
attempt to subclassify male breast carcinomas based on the
immunoprofile, and to evaluate the association of the subtypes
with histologic type, nuclear grade, lymph node status, clinical
stage, and expression of EGFR and NF-κB.
Materials and methods
Specimens
Slides and paraffin-embedded tissue blocks from 42 male
patients with breast cancer were retrieved from the surgical
pathology archives in the departments of pathology of The Uni-
versity of Texas M. D. Anderson Cancer Center (from 2002 to
2005, Houston, Texas) and the University of Texas Medical
Branch (from 1990 to 2004, Galveston, Texas). Clinical data
for these patients were collected with approval of the Institu-
tional Review Board (IRB# LAB05-0153).
Histologic evaluation
The slides from these cases were reviewed and the histologic
diagnoses recorded in the medical record were confirmed
independently by two pathologists (YMG, MG). The histologic
classification was based on the criteria set by the World
Health Organization. A diagnosis of invasive papillary carci-
noma is rendered when a frankly invasive carcinoma predomi-
nantly in a papillary growth pattern, or in a ductal/solid patterns
but associated with an in situ component of papillary carci-
noma. The modified Black's nuclear grading system was used
for nuclear grading with a three-tire scheme based on abnor-
malities in nuclear size, nuclear membrane, chromatin, and
mitosis.
Immunohistochemistry and interpretation
Tissue sections (4 μm) from each case were prepared for
immunostaining.
After incubation in a 60°C oven overnight and deparaffiniza-
tion, the tissue sections were treated with 3% hydrogen per-
oxide in methanol for five minutes. Following a brief
pretreatment with 0.02% protease XXIV for two minutes, the
slides were incubated with one of the following antibodies:
anti-human ER, PR, HER2, CK5/6, EGFR, and NF-κB. The
Table 1
Antibody characterization, dilutions and positive controls
Antigen Vendors Species (clone) Dilution Positive control
ER Novocastra Lab Ltd. Newcastle, UK Mouse IgG1 (6F11) 1:50 Breast
PR NeoMarkers Inc. Fremont, CA, USA Mouse IgG1 (1A6) 1:30 Breast
HER2 NeoMarkers Inc. Fremont, CA, USA Mouse IgG1 (e2-4001) 1:100 Breast carcinoma
CK 5/6 Deko Inc, Carpinteria, CA, USA Mouse IgG1 kappa (D5/16 B4) 1:100 Skin
EGFR Zymed Lab Inc. San Francisco, CA, USA Mouse IgG1 (31G7) 1:50 Squamous cell carcinoma
NF-κB p56 Abcam Inc. Cambridge, MA, USA Rabbit polyclonal IgG 1:80 Large B cell lymphoma
CK = cytokeratin; EGFR = epidermal growth factor receptor; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; NF-κB 
= nuclear factor-κB; PR = progesterone receptor.Available online http://breast-cancer-research.com/content/11/3/R28
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sources and characterization of these antibodies are detailed
in Table 1. The immunostains were performed using an auto-
mated staining system (BenchMark XT, Ventana Medical Sys-
tem Inc., Tucson, AZ, USA). Mouse Envision (DAKO Corp., St.
Barbara, CA, USA) was used as secondary antibody. The
color was visualized by incubation with chromagen DAB for 16
minutes. The slides were then counterstained with Mayer
hematoxylin and a coverslip with Permount (Fisher Scientific,
Fair Lawn, NJ, USA) was placed on the slide.
The staining patterns and intensities for each of the markers
were interpreted by two pathologists independently (YMG,
MG). For ER and PR, nuclear staining in more than 10% of
tumor cells was classified as positive staining. A positive
HER2 stain was determined by greater than 2+ membranous
staining of tumor cells based on the conventional three-tier
grading criteria. All cases with greater than 2+ HER2 immu-
nostain were further confirmed by fluorescence in situ hybrid-
ization (FISH) study. An estimation of more than 10% of tumor
cells with membranous or cytoplasmic staining was required
for a positive interpretation of EGFR and CK5/6. The NF-κB
staining demonstrated a nuclear staining pattern, and if more
than 10% of tumor cells stained, the specimen was consid-
ered to be positive.
FISH for HER2 amplification
The HER2 DNA probe kit (PathVysion; Vysis, Downers Grove,
IL, USA) included two DNA probes directly labeled with differ-
ent fluorescent dyes: the Spectrum-Orange fluorophore-
labeled HER2 (190 kb) specific for the HER2 gene locus on
chromosome 17q11.2-q12, and the Spectrum-Green fluoro-
phore-labeled chromosome enumerator probe (5.4 kb) target-
ing the alpha satellite DNA sequence located at the
centromeric region of chromosome 17 (CEP17; 17p11.1-
q11.1).
FISH assay was performed according to the protocol provided
by Vysis (Downers Grove, IL, USA). Routinely processed par-
affin-embedded tissue sections (4 μm) were deparaffinized in
three changes of fresh xylene for three minutes each, dehy-
drated in two changes of 100% ethanol for three minutes
each, and then allowed to air dry. Slides were then placed in a
preheated 80°C pretreatment reagent (1 M sodium isothiocy-
anate;Vysis, Downers Grove, IL, USA) for 13 minutes, rinsed
in distilled water for three minutes, and allowed to air dry. Pro-
tease digestion was accomplished by placing the slides in a
prewarmed 37°C protease solution (Vysis, Downers Grove, IL,
USA) for 13 minutes. Samples were then rinsed in distilled
water for three minutes and air-dried. All slides were hybridized
under identical conditions and with appropriate control tissue.
An aliquot of pre-diluted LSI HER-2 Spectrum-Orange/
CEP17 Spectrum-Green (Vysis, Downers Grove, IL, USA)
was applied to the region of interest on the slide. A coverslip
was placed and sealed at the periphery with rubber cement.
The slides were placed on a preprogrammed, humidified slide
warmer (Hybrite; Vysis, Downers Grove, IL, USA) with the fol-
lowing settings: denaturation at 73°C for five minutes and
hybridization at 37°C for 16 hours. After hybridization, the rub-
ber cement was removed, and the coverslip was floated off by
soaking the slides in two times standard saline citrate buffer
with 0.3% Nonidet P-40 (2 × SSC/0.3% NP-40) at ambient
temperature. The slides were incubated in pre-warmed 2 ×
SSC/0.3% NP-40 at 73°C for two minutes, immersed in 2×
SSC/0.3% NP-40 at ambient temperature for one minute, air
dried in the dark, counterstained with 7 ml of 4,6-diamidino-2-
phenylindole dihydrochloride (DAPI; Vysis, Downers Grove, IL,
USA), and a coverslip was placed on the slide.
The signals were enumerated using an epifluorescence micro-
scope (Olympus AX70; Melville, NY, USA) fitted with a Spec-
trum-Orange, Spectrum-Green, and DAPI triple-filter set. At
least 60 cells were scored in each preparation, and the copy
numbers of HER2 and CEP17 for each cell were recorded.
HER2 was quantified using the ratio of HER2 to CEP17 signal
counts. HER2 gene amplification was defined as an HER2 to
CEP17 signal ratio of 2.0 or greater. Polysomy of chromosome
17 was defined as the presence of three or more CEP17 sig-
nals in more than 6% of the tumor cells evaluated.
IHC subtyping criteria
The IHC-based definition of breast cancer subtypes used in
this study was as follows: luminal A (ER+ and/or PR+, HER2-
), luminal B (ER+ and/or PR+, HER2+), HER2+/ER- (ER-, PR-
, HER2+), and basal-like (ER-, PR-, HER2-, CK5/6+) [9].
Statistical analysis
Descriptive statistics were calculated. Fisher's exact tests
were used to assess the association between categorical var-
iables. P values (two-sided test) of less than 0.05 were consid-
ered significant. All statistical analyses were carried out using
SAS 8.0 (SAS Institute, Cary, NC, USA).
Results
The clinicopathological features of breast carcinoma from 42
men are summarized in Table 2. The racial distribution was as
follows: 28 Caucasians, seven African Americans and seven
Hispanics. Ages of the patients ranged from 33 to 82 years
with a mean age of 63 years. Patients with luminal B subtype
tumor was slightly younger than those with luminal A subtype
(mean age 58 vs. 64 years, respectively), but the difference
was not statistically significant (P = 0.25). Most of the patients
were diagnosed with stage I to II disease (81%, 34/42) and
were treated surgically (95%, 40/42), either by lumpectomy or
mastectomy. Many patients also received other treatments
including hormonal therapy (88%, 36/42), chemotherapy
(64%, 27/42, with 2/27 received pre-operatively), and radia-
tion therapy (19%, 8/42). There were no significant differ-
ences identified between the subtypes of male breast cancer
regarding patients' race, presence of distant metastasis, and
clinical stage.Breast Cancer Research    Vol 11 No 3    Ge et al.
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Histologic features of subtypes
The histologic variants of male breast carcinoma were as fol-
lows: 37 (88%) were invasive ductal carcinomas and five were
invasive papillary carcinomas (12%). All seven tumors of lumi-
nal B subtype were histologically invasive ductal carcinoma.
Invasive papillary carcinomas were seen only in luminal A sub-
type (Table 2).
More than half of the luminal A tumors (60%, 21/35) had inter-
mediate nuclear grade (modified Black's nuclear grade 2) and
one-third of them (34%, 12/35) had high nuclear grade (grade
3). Low nuclear grade tumors (nuclear grade 1) were seen
only in luminal A subtype (n = 2). In comparison, high nuclear
grade (grade 3) tumors were more frequent in luminal B sub-
type (71%, 5/7, Figure 1a) than in luminal A subtype (P =
0.09, Table 2).
Patients with luminal B subtype carcinomas had an increased
tendency to have lymph node involvement (71%, 5/7) com-
pared with patients with luminal A subtype tumors (41%, 14/
35). Furthermore, the mean number of positive lymph nodes
observed in luminal B subtype (2.2) was slightly higher than
that seen in luminal A subtype (1.8). None of these differences
were statistically significant (Table 2).
Immunostain profile of male breast cancer
The expression frequencies of the immunomarkers in our male
breast carcinoma samples are summarized in Table 3. ER was
expressed in all tumors, while 64% of them were PR+. Among
the tumors tested equivocal (++) or positive (+++) for HER2
on immunostain, seven were confirmed by positive FISH tests
with HER2-to-CEP17 signal ratio of 2.0 or more. Based on the
immunophenotyping and FISH study, the most common sub-
Table 2
Clinicopathologic characteristics of subtypes
Subtypes Luminal A
(n = 35)
Luminal B
(n = 7)
Total
(n = 42)
P value*
Demographics
Mean age (years) 64 58 63 0.25
Race
Caucasian 22 6 28
African American 6 1 7
Hispanic 7 0 7
Histologic type
Invasive ductal carcinoma 30 7 37 (88%)
Invasive papillary carcinoma 5 0 5 (12%)
Other types 0 0 0
Nuclear grade 0.06
12 0 2
22 1 2 2 3
31 2 5 1 7
Cases with positive lymph node 14 (41%) 5 (71%) 19 (45%) 0.40
Mean number of positive lymph nodes 1.5 2.3 1.6 0.40
Stage grouping
I9 1 1 0
IIA 10 3 13
IIB 9 2 11
IIIA 2 0 2
IIIB 4 1 5
IV 1 0 1
* Fisher's exact test.Available online http://breast-cancer-research.com/content/11/3/R28
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type in our group of male breast carcinoma was luminal A sub-
type (78%, 33/42), which was followed by luminal B subtype
(17%, 7/42). There were no HER2+/ER-, basal-like, or unclas-
sified subtypes observed in this group. Luminal A tumors
tended to have a slight higher frequency of PR expression
(69%, 24/35) than luminal B subtype (43%, 3/7). CK5/6 was
expressed in 12% of the male breast carcinomas (Table 3),
and expression was slightly more common in luminal B tumors
(43%, 3/7) than luminal A subtype (26%, 9/35). By definition,
over-expression and amplification of HER2 was demonstrated
in all seven luminal B tumors (Figure 1b).
Positive EGFR stain was observed in 21% (9/42) of the sam-
ples; this staining was more frequently seen in carcinoma of
luminal B subtype (42%, 3/7) than in luminal A subtype (17%,
6/35, Table 3). The staining pattern of EGFR in luminal B sub-
type tumors was diffuse and strong (Figure 1c), frequently
intensifying at the leading edges of tumor invasion. In contrast,
EGFR staining in luminal A subtype carcinoma was weak and
focal. NF-κB nuclear staining was demonstrated in 40% (17/
42) of tumors (Figure 1d). A higher frequency of NF-κB
expression was observed in tumors of luminal B subtype
(57%, 4/7) than those of luminal A subtype (37%, 13/35,
Table 3). However, significant differences in expression of
above immunomarkers were not observed between the two
subtypes, probably owing to the small study group (Table 3).
Discussion
Although the molecular subtypes of breast cancer were origi-
nally identified by gene expression analysis using DNA micro-
arrays, IHC markers have been used as surrogates for DNA
microarray in subtyping breast cancer. Based on recent
updated IHC subtype definitions [9], we identified two molec-
ular subtypes of male breast carcinoma in our group as luminal
A (83%) and luminal B (17%) subtypes. Basal-like, HER2+/
ER-, and unclassified subtypes were not observed in this
group. This distribution differs from large study series in female
breast carcinoma [8,9,24,25], which reported much lower fre-
quencies of luminal A subtype (51 to 69%) but significantly
higher frequencies of basal-like (12 to 21%) and HER2+/ER-
(7 to 12%) subtypes. Our study also showed that male breast
carcinomas in this group universally expressed ER (100%), a
significantly higher frequency than that in female breast carci-
nomas (60 to 69%) [4,9]. This result was in agreement with
previous studies showing that male breast carcinoma has a
higher percentage of ER positivity (81 to 100%) than female
breast cancer or gynecomastia [4,23,26,27]. The knowledge
of immunophenotype-based subtyping of male breast carci-
noma may be applied in comparison of treatment responses
and prognosis in matched subtypes of female breast carci-
noma.
The HER2/neu gene is a member of a gene family encoding
transmembrane receptors for growth factors, including EGFR,
HER2, HER3, and HER4. Approximately 25 to 30% of invasive
female breast cancers over-express HER2 [28]. However,
studies of HER2 over-expression in male breast cancer are
limited with conflicting results. Pooled data demonstrated that
HER2 over-expression detected by IHC was in a range of 2 to
56% with an average of 23% (reviewed in [29]). The inconsist-
ency in percentage of positive HER2 immunostain may be due
to differences in antibody preparation, scoring systems, and
cut-off values used in these studies. A recent study of 99
cases of male breast cancer demonstrated that 15% of the
tumors were 2+ (equivocal) or 3+ (positive) on HER2 immu-
nostain and 11% were positive using FISH analysis [29]. In the
current study, we detected 7 of 42 (16%) of male breast can-
Figure 1
Photographs of a luminal B subtype of male breast cancer with H&E  immunohistochemical stains Photographs of a luminal B subtype of male breast cancer with H&E 
immunohistochemical stains. The luminal B tumor demonstrated histo-
logic features of (a) invasive ductal carcinoma with high nuclear grade. 
The tumor showed (b) strong membraneous stain (3+) of human epi-
dermal growth factor receptor 2 (HER2), (c) diffuse cytoplasmic stain-
ing of epidermal growth factor receptor (EGFR), and (d) nuclear 
staining of nuclear factor-κB (NF-κB).
Table 3
Immunohistochemical results of male breast carcinoma
Immunostains Luminal A
n = 35
Luminal B
n = 7
Total P value*
ER 35 7 42 (100%)
PR 24 3 27 (64%) 0.23
HER2 0 7 7 (16%)
CK 5/6 9 3 12 (28%) 0.39
EGFR 6 3 9 (21%) 0.16
NF-κB1 3 4 1 7  ( 4 0 % ) 0 . 4 1
* Fisher's exact test.
CK = cytokeratin; EGFR = epidermal growth factor receptor; ER = 
estrogen receptor; HER2 = human epidermal growth factor receptor 
2; NF-κB = nuclear factor-κB; PR = progesterone receptor.Breast Cancer Research    Vol 11 No 3    Ge et al.
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cers with HER2 gene amplification determined using both IHC
(3+) and FISH analysis. Although the early data tended to
show higher percentages of positive HER2 immunostain, we
believe that true HER2-positive cases in male breast cancer
are probably fewer than those of female breast carcinoma
when the current American Society of Clinical Oncology/Col-
lege of American Pathologists guidelines for IHC with FISH
analysis are applied.
Over-expression of HER2 is a well-known prognostic factor
associated with poor survival in women with breast carcinoma
[5,28]. However, the data are limited in male breast cancer
regarding the association between HER2 over-expression and
survival. In an early analysis of 17 cases of invasive male breast
cancer, HER2 over-expression was detected by IHC in seven
(41%) patients who were associated with significantly short-
ened survival [30]. Nevertheless, in a recent study, male breast
cancers failed to show an association between HER2 over-
expression and lymph node metastasis, a known unfavorable
prognostic factor [29]. In our study, the luminal B subtype
tumors (phenotype HER2+/ER+ and/or PR+) were more fre-
quently associated with high nuclear grade, an unfavorable
factor in both women and men [31]. More frequently, patients
with luminal B subtype tumors had nodal metastasis and an
increased number of positive lymph nodes. Although these
findings suggest that carcinoma with HER2 over-expression
may be associated with unfavorable prognostic factors, the
differences were statistically insignificant due to our small
cohort and a relatively short period of follow-up. Obviously, a
high percentage of ER expression in male breast carcinoma is
inevitably associated with the rarity of HER2+/ER- subtype
carcinoma, which reportedly has a worse prognosis than that
of luminal B tumors (HER2+/ER+ or PR+) in female patients.
This may raise questions on the correlation in prognosis of the
breast cancer subtypes between males and females. It is
unknown whether the paucity or absence of the unfavorable
breast carcinoma subtypes in males, such as HER2+/ER-,
basal-like, or unclassified subtypes, is associated with a favo-
rable prognosis. It is equally important whether the same sub-
types of breast carcinoma have similar responses to therapy in
males compared with females. To answer these questions, fur-
ther investigation by comparison of prognosis and therapy
responses with matched subtypes of breast carcinoma in
males and females is warranted.
Based on studies in female patients with breast cancer, EGFR
was reportedly over-expressed in aggressive [10-13] and met-
astatic breast carcinomas [32]. In breast carcinomas with
EGFR over-expression, NF-κB was reportedly activated [17],
which was also linked to unfavorable prognosis by promoting
tumor metastasis and inhibiting apoptosis [18,20]. The data
on EGFR expression in male breast cancer are very limited
with only a few earlier studies conducted more than a decade
ago. The reported expression rate of EGFR in male breast car-
cinomas varied significantly from 8.5% to 76% [31,33,34],
probably due to variations in antibody preparation, staining
protocol, and interpretation criteria. In our study, 21% of the
tumors expressed EGFR, which is in agreement with one of
the previous studies (20%) [31]. Interestingly, we found
stronger EGFR staining was present at the leading edge of
tumor invasion in high-grade tumors of luminal B subtype. We
speculate that the higher expression rates for EGFR and NF-
κB in luminal B subtype is an important factor contributing to
their aggressive behavior and poor clinical prognosis. How-
ever, although higher expression rates of EGFR and NF-κB
were observed in the luminal B subtype than those in the lumi-
nal A subtype, the difference lacked statistical significance
due to the small study group.
In summary, the current study attempts to characterize sub-
types of male breast cancer by using IHC markers. It provides
new information for future study on prognosis, drug trials, and
clinical management of breast cancer in men. However, our
data need to be interpreted with caution for several reasons.
Firstly, the study was designed on the basis of published data
from female breast cancer that allowed subclassification of
these tumors according to their characteristic features in DNA
microarray and expression profiles [5,7]. DNA microarray data
on male breast cancer are currently not available because of
the rarity of this malignancy. Therefore, it is uncertain whether
the gender differences present in these tumors regarding the
genetic features and associated expression profiles. Sec-
ondly, the current study was unable to provide correlative data
between the immunosubtypes of male breast cancer and their
clinical behavior and survival information due to a relatively
short period of follow-up. It is certainly critical in future studies
to identify the subtypes of male breast carcinoma and their
association with survival as well as the candidate markers with
potential prognostic and predictive values. Finally, due to the
rarity of the disease, the small number of cases collected in
this group may affect validation of its conclusion and the sta-
tistical power of the observations. Additional studies with
larger numbers of patients are needed to achieve sufficient
statistical power.
Conclusions
Our study demonstrates that luminal A and luminal B subtypes
are the major subtypes of male breast carcinoma. The immu-
nophenotypical features of male breast cancer differ from
those of its female counterpart. Luminal B tumors tend to have
high nuclear grade and more frequent expression of EGFR
and NF-κB.
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